Adjustment of the nominal value of Neovacs shares

On April 2, 2025, Neovacs, a preclinical biopharmaceutical company listed on Euronext Growth Paris, announced a reduction in the par value of its shares. The Board of Directors decided, in accordance with a resolution of the 2024 General Meeting, to reduce the par value of each share from €0.05 to €0.01. As a result, the company's share capital decreased from €241,603.85 to €48,320.77, still distributed among 4,832,077 shares.

This capital reduction follows losses incurred by the company and the need to adjust its financial structure. Shareholders should nevertheless remain cautious regarding dilution risks and pressure on the share price, caused by dilutive financing transactions already undertaken.